Abstract: This study employs network pharmacology methods to systematically investigate the intervention mechanisms of Ganoderma lucidum mycelium powder ethanol extract（DA）in non-alcoholic fatty liver disease（NAFLD）.The components of DA were identified using LC-MS, and its active ingredients were screened based on ADME models. The targets of these active ingredients were predicted via the Swiss Target Prediction platform, while NAFLD-related targets were retrieved from the Gene Cards and OMIM databases. A PPI network was constructed using Cytoscape software to screen for core targets, the enrichment analysis was then performed using the DAVID database, with molecular docking validation ultimately completed via AutoDock. The results of this study indicated that 115 compound components were identified from DA by LC-MS, and 53 active ingredients were screened. These active ingredients and NAFLD exhibited 250 shared targets, from which 26 core targets were identified through screening via the Protein-Protein Interaction（PPI） network. Enrichment analysis revealed that these targets were significantly enriched in signaling pathways such as PI3K-Akt, MAPK, and AGE-RAGE, and were involved in processes including inflammatory response, signal transduction, and transcriptional regulation. Molecular docking demonstrated that core components（e.g., DA39）exhibited strong binding affinity with the targets. This study suggests that DA likely exerts its anti-NAFLD effects by mitigating insulin resistance, regulating lipid metabolism, reducing inflammation, and countering fibrosis through a synergistic "multi-compound-target-pathway", reflecting the holistic therapeutic characteristics of traditional Chinese medicine.